Table 1.
Characteristics of the control subjects and the patients with systemic sclerosis (SSc)
| SSc Registry cohort |
UT Division cohort |
|||||
|---|---|---|---|---|---|---|
| White | Black | Hispanic | White | Black | Hispanic | |
| Controls | ||||||
| Sex | ||||||
| n* | 421 | 63 | 23 | 277 | 138 | 116 |
| Female, no. (%) | 198 (47.0) | 36 (57.1) | 15 (65.2) | 155 (56.6) | 106 (77.4) | 65 (56.0) |
| Male, no. (%) | 223 (53.0) | 27 (42.9) | 8 (34.8) | 119 (43.4) | 31 (22.6) | 51 (44.0) |
| SSc patients | ||||||
| Sex | ||||||
| n | 745 | 69 | 66 | 314 | 108 | 100 |
| Female, no. (%) | 676 (90.7) | 61 (88.4) | 58 (87.9) | 259 (82.5) | 90 (83.3) | 90 (90.0) |
| Male, no. (%) | 69 (9.3) | 8 (11.6) | 8 (12.1) | 55 (17.5) | 18 (16.7) | 10 (10.0) |
| Skin involvement | ||||||
| n | 712 | 67 | 60 | 292 | 97 | 97 |
| Limited cutaneous SSc, no. (%) | 465 (65.3) | 25 (37.3) | 28 (46.7) | 146 (50.0) | 28 (28.9) | 38 (39.2) |
| Diffuse cutaneous SSc, no. (%) | 247 (34.7) | 42 (62.7) | 32 (53.3) | 146 (50.0) | 69 (71.1) | 59 (60.8) |
| Antibodies | ||||||
| n | 509 | 43 | 45 | 158 | 43 | 60 |
| Anticentromere, no. (%) | 221 (43.4) | 4 (9.3) | 12 (26.7) | 79 (50.0) | 8 (18.6) | 17 (28.3) |
| Anti–topoisomerase I, no. (%) | 138 (27.1) | 22 (51.2) | 14 (31.1) | 36 (22.8) | 21 (48.8) | 25 (41.7) |
| Anti–RNA polymerase III, no. (%) | 150 (29.5) | 17 (39.5) | 19 (42.2) | 43 (27.2) | 14 (32.6) | 18 (30.0) |
*
Data missing in 3 white controls and 1 black control in the University of Texas SSc cohort (UT Division cohort).